<DOC>
	<DOCNO>NCT01759472</DOCNO>
	<brief_summary>To determine whether LTD4-BPT could effective indicator predict efficacy anti-leukotriene therapy , allow objective proof use LTRA among asthmatic specific sensitive leukotriene population asthma . Hypothesis ：Monteluakst good improve pre-challenge FEV1 baseline leukotriene-sensitive group leukotriene-insensitive group .</brief_summary>
	<brief_title>Effect Study Montelukast Treat Asthma Detected LTD4 Bronchial Effect Study Montelukast Treat Asthma Detected LTD4 Bronchial Provocation Test</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Ascorbic Acid</mesh_term>
	<mesh_term>Leukotriene Antagonists</mesh_term>
	<mesh_term>Montelukast</mesh_term>
	<criteria>1 . Aged 1560 year , male female . 2 . Mild moderate persistent asthma . 3 . Mini AQLQ score ≤6 ACQ score ≥1 . 4 . Giving write informed consent . 1 . Current smoker quit smoke ≤12 month . 2 . Significant allergen exposure . 3 . Respiratory tract infection within 2 week study . 4 . Cardiovascular disease . 5 . History malignant disease within precede 5 year . 6 . And/or concomitant pulmonary disease . 7 . Pregnant breastfeed period . 8 . Use leukotrienes receptor antagonist within 5 day</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>leukotriene</keyword>
	<keyword>leukotriene receptor antagonist</keyword>
</DOC>